Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis. (28th September 2015)

• Record Type: Journal Article
• Authors: Yoshida, Junko; Wicks, Robert T.; Zambrano, Andrea I.; Tyler, Betty M.; Javaherian, Kashi; Grossman, Rachel; Daoud, Yassine J.; Gehlbach, Peter; Brem, Henry; Stark, Walter J.
• Other Names: Dreyfuss Juliana L. Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2015(2015)
• Publication Date: 2015-09-28
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2015/137136
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : We assessed the antiangiogenic effects of subconjunctival injection of Fc-endostatin (FcE) using a human vascular endothelial growth factor-induced rabbit corneal neovascularization model. Angiogenesis was induced in rabbit corneas through intrastromal implantations of VEGF polymer implanted 2 mm from the limbus. NZW rabbits were separated into groups receiving twice weekly subconjunctival injections of either saline; 25 mg/mL bevacizumab; 2 mg/mL FcE; or 20 mg/mL FcE. Corneas were digitally imaged at 5 time points. An angiogenesis index (AI) was calculated (vessel length (mm) × vessel number score) for each observation. All treatment groups showed a significant decrease in the vessel length and AI compared to saline on all observation days (P < 0.001 ). By day 15, FcE 2 inhibited angiogenesis significantly better than FcE 20 (P < 0.01 ). There was no significant difference between FcE 2 and BV, although the values trended towards significantly increased inhibition by BV. BV was a significantly better inhibitor than FcE 20 by day 8 (P < 0.01 ). FcE was safe and significantly inhibited new vessel growth in a rabbit corneal neovascularization model. Lower concentration FcE 2 exhibited better inhibition than FcE 20, consistent with previous FcE studies referencing a biphasic dose-response curve. Additional studies are necessary to further elucidate the efficacy and clinical potential of this novel angiogenesis inhibitor.